Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EBITDA (2023 - 2025)

Monte Rosa Therapeutics' EBITDA history spans 3 years, with the latest figure at -$46.7 million for Q4 2025.

  • For Q4 2025, EBITDA fell 476.64% year-over-year to -$46.7 million; the TTM value through Dec 2025 reached -$39.1 million, up 46.68%, while the annual FY2025 figure was -$39.1 million, 46.68% up from the prior year.
  • EBITDA reached -$46.7 million in Q4 2025 per GLUE's latest filing, down from -$27.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $46.9 million in Q1 2025 to a low of -$46.7 million in Q4 2025.
  • Average EBITDA over 3 years is -$20.7 million, with a median of -$31.0 million recorded in 2023.
  • The largest YoY upside for EBITDA was 246.89% in 2025 against a maximum downside of 476.64% in 2025.
  • A 3-year view of EBITDA shows it stood at -$34.5 million in 2023, then skyrocketed by 135.93% to $12.4 million in 2024, then tumbled by 476.64% to -$46.7 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's EBITDA are -$46.7 million (Q4 2025), -$27.0 million (Q3 2025), and -$12.3 million (Q2 2025).